Medtronic (NYSE:MDT) Stock Gets Price Target Boost from BTIG Research

Medtronic (NYSE:MDT – Get Free Report) had its target price hoisted by investment analysts at BTIG Research from $99.00 to $109.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical technology company’s stock. BTIG Research‘s price target indicates a potential upside of 9.14% from the company’s current price.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company increased their target price on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a report on Wednesday, September 2nd. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a report on Monday, November 16th. Bank of America boosted their price target on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Weiss Ratings raised shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Finally, Mizuho set a $115.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.17.

Get Our Latest Research Report on Medtronic

Medtronic Stock Down 0.7%

Shares of NYSE:MDT opened at $99.88 on Thursday. The stock has a market cap of $127.75 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 2.41 and a beta of 0.56. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. Medtronic has a 12-month low of $73.31 and a 12-month high of $106.33. The business’s 50 day moving average is $94.62 and its 200 day moving average is $88.45.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts forecast that Medtronic will post 5.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. This represents a 8.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,903 shares of company stock worth $5,889,203 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of Medtronic

Large investors have recently added to or reduced their stakes in the stock. Meramec Financial Planners LLC raised its position in shares of Medtronic by 4.9% in the 3rd quarter. Meramec Financial Planners LLC now owns 2,171 shares of the medical technology company’s stock worth $187,000 after acquiring an additional 101 shares in the last quarter. Genesis Private Wealth LLC boosted its position in shares of Medtronic by 2.0% during the third quarter. Genesis Private Wealth LLC now owns 5,170 shares of the medical technology company’s stock valued at $446,000 after purchasing an additional 103 shares in the last quarter. LightSquare Wealth Management LLC boosted its position in shares of Medtronic by 3.6% during the third quarter. LightSquare Wealth Management LLC now owns 2,932 shares of the medical technology company’s stock valued at $253,000 after purchasing an additional 103 shares in the last quarter. Kennebec Savings Bank grew its stake in Medtronic by 1.2% in the third quarter. Kennebec Savings Bank now owns 9,201 shares of the medical technology company’s stock worth $794,000 after purchasing an additional 110 shares during the period. Finally, Petredis Investment Advisors LLC grew its stake in Medtronic by 0.4% in the third quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock worth $2,275,000 after purchasing an additional 114 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Medtronic

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Articles

Analyst Recommendations for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.